Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

V3: HIV's switch-hitter.

Oliver Hartley1, Per Johan Klasse, Quentin J Sattentau

  • 1Department of Structural Biology and Bioinformatics, Centre Medical Universitaire, Geneva, Switzerland.

AIDS Research and Human Retroviruses
|February 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Learned young: HIV-1 germline-targeting vaccination in infants.

Current opinion in HIV and AIDS·2026
Same author

Decoding epitope immunodominance in HIV Env using cryoEM and machine learning.

bioRxiv : the preprint server for biology·2026
Same author

CCL3 is produced by aged neutrophils across cancers and promotes tumor growth.

Cancer cell·2026
Same author

HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial.

Nature communications·2025
Same author

A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.

Journal of virology·2025
Same author

Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping.

Nature communications·2025
Same journal

Identification of a Complex HIV-1 Circulating Recombinant Form (CRF203_cpx) Originating from Three Main Circulating Recombinant Forms in China.

AIDS research and human retroviruses·2026
Same journal

Near Full-Length Genome Characterization of a Novel Second-Generation HIV-1 CRF01_AE/CRF07_BC Recombinant Identified in an MSM Individual in Guizhou, China.

AIDS research and human retroviruses·2026
Same journal

Evolving Indications and Diagnostic Spectrum of Bone Marrow Examination in People with HIV During the Antiretroviral Therapy Era: A 6-Year Retrospective Study.

AIDS research and human retroviruses·2026
Same journal

A Conserved Natural Killer Cell Transcriptional Fingerprint in Rhesus Macaque Models of Acute Viral Infections.

AIDS research and human retroviruses·2026
Same journal

Perceived Ethical Risks of HIV Phylogenetic Research: Insights from Professional Stakeholders in Uganda.

AIDS research and human retroviruses·2026
Same journal

Genomic Characterization of Two Novel Human Immunodeficiency Virus-1 Recombinant Forms (CRF01_AE and B) in Men Who Have Sex with Men in Hebei, China.

AIDS research and human retroviruses·2026
See all related articles

The V3 region of the HIV-1 gp120 envelope glycoprotein significantly impacts viral tropism and drug resistance. Recent findings question its utility as a vaccine target, suggesting new directions for HIV-1 therapeutics and vaccines.

Area of Science:

  • Virology
  • Immunology
  • Drug Discovery

Background:

  • The V3 variable region of the gp120 surface envelope glycoprotein is crucial for HIV-1 tropism.
  • V3 influences coreceptor usage (CCR5/CXCR4) and subsequent cellular infection.
  • It also affects HIV-1 sensitivity to entry inhibitors and antibody neutralization.

Purpose of the Study:

  • To review recent advances in understanding the V3 region's role in HIV-1.
  • To discuss the implications of new V3 knowledge for HIV-1 drug and vaccine development.

Main Methods:

  • Literature review of recent findings on V3 structure, function, antigenicity, and immunogenicity.
  • Analysis of V3's impact on viral tropism, coreceptor usage, and drug resistance.
  • Evaluation of V3 as a target for HIV-1 neutralizing antibodies and vaccines.

Related Experiment Videos

Main Results:

  • The V3 region is a key determinant of HIV-1 tropism, dictating CCR5 or CXCR4 coreceptor use.
  • V3 sequence variations influence HIV-1's susceptibility to entry inhibitors and its ability to develop resistance.
  • Despite historical focus, V3's efficacy as a vaccine target remains questionable due to recent findings.

Conclusions:

  • New insights into V3's structure and function offer opportunities for novel HIV-1 drug development.
  • The immunogenicity and antigenicity of V3 present challenges for its use as a universal vaccine target.
  • Further research is needed to leverage V3-related knowledge for effective HIV-1 prevention and treatment strategies.